» Articles » PMID: 34536215

The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy!

Overview
Date 2021 Sep 18
PMID 34536215
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoglobulin E (IgE) is a well-known key factor in allergic airway disease; however, its central role in non-allergic airway inflammation is often underestimated. In some airway diseases, IgE is produced as a result of allergic sensitization. However, in others, IgE production occurs despite the lack of a specific allergen. Although multiple pathways contribute to the production of IgE in airway disease, it is its activity in mediating the inflammatory response that is associated with disease. Therefore, an understanding of IgE as the unifying component of upper and lower airway diseases has important implications for both diagnosis and treatment. Understanding the role of IgE in each upper and lower airway disease highlights its potential utility as a diagnostic marker and therapeutic target. Further classification of these diseases by whether they are IgE mediated or non-IgE mediated, rather than by the existence of an underlying allergic component, accounts for both systemic and localized IgE activity. Improvements in diagnostic methodologies and standardization of clinical practices with this classification in mind can help identify patients with IgE-mediated diseases. In doing so, this group of patients can receive optimal care through targeted anti-IgE therapeutics, which have already demonstrated efficacy across numerous IgE-mediated upper and lower airway diseases.

Citing Articles

Changes in Respiratory Sensitivity Status of Patients in a Hospital in Shanxi Province Before and After the COVID-19 Epidemic.

Dong C, Hu F, Ma Z, Ma X, Zhang L, Li Y J Asthma Allergy. 2025; 18:339-348.

PMID: 40066294 PMC: 11892735. DOI: 10.2147/JAA.S497018.


EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.

Scadding G, Conti D, Scheire S, Backer V, Blaiss M, Cardell L Front Allergy. 2025; 5:1531788.

PMID: 39963330 PMC: 11830706. DOI: 10.3389/falgy.2024.1531788.


Serum T2-High Inflammation Mediators in Eosinophilic COPD.

Januskevicius A, Vasyle E, Rimkunas A, Palacionyte J, Kalinauskaite-Zukauske V, Malakauskas K Biomolecules. 2025; 14(12.

PMID: 39766355 PMC: 11674300. DOI: 10.3390/biom14121648.


Eosinophilic inflammation: a key player in COPD pathogenesis and progression.

Lee Y, Heriyanto D, Yuliani F, Laiman V, Choridah L, Lee K Ann Med. 2024; 56(1):2408466.

PMID: 39624959 PMC: 11459840. DOI: 10.1080/07853890.2024.2408466.


High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity.

Aswad M, Pechkovsky A, Ghanayiem N, Hamza H, Dotan Y, Louria-Hayon I Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459021 PMC: 11510504. DOI: 10.3390/ph17101382.


References
1.
Okubo K, Okano M, Sato N, Tamaki Y, Suzuki H, Uddin A . Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized Study. J Allergy Clin Immunol Pract. 2020; 8(9):3130-3140.e2. DOI: 10.1016/j.jaip.2020.04.068. View

2.
Kamin W, Kopp M, Erdnuess F, Schauer U, Zielen S, Wahn U . Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2009; 21(1 Pt 2):e160-5. DOI: 10.1111/j.1399-3038.2009.00900.x. View

3.
Celebi Sozener Z, Aydin O, Misirligil Z, Mungan D, Demirel Y, Celik G . Omalizumab in non-allergic Asthma: A report of 13 cases. J Asthma. 2017; 55(7):756-763. DOI: 10.1080/02770903.2017.1362427. View

4.
Rondon C, Dona I, Lopez S, Campo P, Romero J, Torres M . Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response. Allergy. 2008; 63(10):1352-8. DOI: 10.1111/j.1398-9995.2008.01695.x. View

5.
Shiomori T, Yoshida S, Miyamoto H, Makishima K . Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis. J Allergy Clin Immunol. 2000; 105(3):449-54. DOI: 10.1067/mai.2000.104256. View